# Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

> **NCT04362137** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 432 (actual)

## Conditions studied

- Cytokine Storm (Covid-19)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04362137
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-02
- **Primary completion:** 2020-10-17
- **Final completion:** 2020-10-17
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2021-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362137, "Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04362137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*